Free Trial
NASDAQ:GRI

GRI Bio Q2 2024 Earnings Report

GRI Bio logo
$1.46 +0.06 (+4.29%)
As of 04:00 PM Eastern

GRI Bio EPS Results

Actual EPS
-$83.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GRI Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GRI Bio Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

GRI Bio's Q3 2025 earnings is scheduled for Thursday, November 13, 2025, with a conference call scheduled on Friday, November 14, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

GRI Bio Earnings Headlines

Washington prepares for war
While the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.tc pixel
See More GRI Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email.

About GRI Bio

GRI Bio (NASDAQ:GRI), a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

View GRI Bio Profile

More Earnings Resources from MarketBeat